The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS) intends to negotiate with the University of California, San Francisco (UCSF) for a multiple-year contract to utilize a small-animal model to evaluate potential therapies for HIV-1 infection. The animal model being used is an immunodeficient mouse engrafted with human fetal thymus and liver (SCID-hu Thy/Liv) and infected with well-characterized isolates of HIV-1. UCSF possesses a unique capability to evaluate potential HIV-1 therapeutics, alone and in combination, for efficacy and toxicity in vivo, in a validated animal model consisting of SCID mice engrafted with human fetal thymus and liver (SCID-hu Thy/Liv) tissue and infected with a diverse panel of well characterized primary isolates and molecular clones of HIV-1. The statute justifying this other than full and open competition is 41 U.S.C. 253(c)1) and FAR 6.302-1. See Numbered Note 22. Point of Contact Nancy Hershey, Contract Specialist, Phone 301-496-0193, Fax (301) 402-0972. Email: [email protected].

Bid Protests Not Available